Cancer Immunotherapy

Phase I/II Clinical Trials Initiated for Immune Stimulants

Published in Cancer Weekly, May 2nd, 2000

Coley Pharmaceutical Group, Inc. (CPG), Wellesley, Massachusetts, has initiated the first of three Phase I/II trials of CpG DNA-based immune stimulants for the treatment of cancer, the company announced.

The initial study, being conducted at the University of Iowa Cancer Center, is designed to evaluate the safety and immune activation of CpG DNA-based products in patients with relapsed or refractory non-Hodgkin's lymphoma. The company's two additional Phase I/II trials in cancer will begin later this quarter in Europe.

"The rapid initiation of these three clinical trials, our first studies of CpG 7909 in cancer patients, demonstrates our commitment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry